Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2804-2810

  Véra, Pierre ^a   Rohrlich, Pierre ^a   Stiévenart, Jean Louis ^a   Elmaleh, Monique ^a   Duval, Michel ^a   Bonnin, François ^a   Bok, Bernard ^a   Vilmer, Etienne ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN PERFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 2442728215     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2804     Document Type: Article

References (30)

1. Russel JA, Powles RL: Neuropathy due to cytosine arabinoside. Br Med J 44:1189-1193, 1974
2. Slavin RE, Dias MA, Saral R: Cytosine arabinoside induced gastrointestinal toxic alteration in sequantial chemotherapeutic protocols: A clinical-pathologic study of 33 patients. Cancer 42:1747-1759, 1978
3. Rudnik SA, Cadman EC, Capizzi RL, et al: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1193-1979, 1979
4. Penta JS, Von Hoff DD, Muggia FM: Hepatotoxicity of combinaison chemotherapy for acute myelocytic leukemia. Ann Intern Med 87:691-694, 1977
5. Rassiga AL, Schartz HJ, Forman WB, et al: Cytarabine-induced anaphylaxis: Demonstration of antibody and successful desensitization. Arch Intern Med 140:425-426, 1980
6. Baker WJ, Royer GL, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 9:679-693, 1991
7. Nand S, Messmore HL, Patel R, et al: Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 4:571-575, 1986
8. Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 10:1563-1568, 1989
9. Rubin EH, Andersen JW, Deborah B, et al: Risk factors for high-dose cytarabine neurotoxicity: An analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 10:948-953, 1992
10. Vaughn DJ, Jarvik JG, Hackney D, et al: High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR 14:1014-1016, 1993
11. Lill DW, Mountz JM, Darji JT: Technetium-99m-HMPAO brain SPECT evaluation of neurotoxicity due to manganese toxicity. J Nucl Med 35:863-866, 1994
12. Wallace EA, Wisniewski G, Zubal G, et al: Acute cocaine effects on absolute cerebral blood flow. Psychopharmacology 128:17-20, 1996
13. Denays R, Makhoul E, Dachy B, et al: Eletroencephalography mapping and 99mTc HMPAO single-photon emission computed omography in carbon monoxide poisoning. Ann Emerg Med 24:947-952, 1994
14. Osterlundh G, Bjure J, Lannering B, et al: Studies of cerebral blood flow in children with acute lymphoblastic leukemia: Case reports of six children treated with methotrexate examined by single photon emission computed tomography. J Pediatr Hematol Oncol 19:28-34, 1997
15. Karabacak NI, Ozturk G, Gucuyener K, et al: Assessment of brain perfusion by 99mTc-HMPAO SPECT in akinetic mutism due to high-dose intravenous methotrexate therapy. Childs Nerv Syst 13:560-562, 1997
16. Piepsz A, Hahn K, Roca I, et al: A radiopharmaceuticals schedule for imaging in paediatrics: Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl Med 17:127-129, 1990
17. Véra P, Farman-Ara B, Stiévenart JL, et al: Proportional anatomical stereotactic atlas for visual interpretation of brain SPET perfusion images. Eur J Nucl Med 23:871-877, 1996
18. Harila-Saari AH, Ahonen AKA, Vainionpää LK, et al: Brain perfusion after treatment of childhood acute lymphoblastic leukemia. J Nucl Med 38:82-88, 1997
19. Stiévenart JL, Véra P, Verstichel P, et al: Neurological applications of single photon emission tomography. Rev Neurol (Paris) 151:619-633, 1995
20. Rowe CC, Berkovic SF, Austin MC, et al: Patterns of post-ictal cerebral blood flow in temporal lobe epilepsy: Qualitative and quantitative analysis. Neurology 26:268-278, 1991
21. Véra P, Kaminska A, Cieuta C, et al: Optimizing the localization of seizure foci in children using subtraction ictal SPECT co-registered to MRI. J Nucl Med 40:786-792, 1999
22. Barrios NJ, Cameron CK, Freeman AI, et al: Toxicity of high dose of ara-C in children and adolescents. Cancer 60:165-169, 1987
23. Salinsky MC, Levine RL, Aubuchon JP, et al: Acute cerebellar dysfunction with high-dose ara-C therapy. Cancer 51:426-429, 1983
24. Barnett MD, Richard MA, Ganesan TS, et al: Central nervous system toxicity of high dose cytosine arabinoside. Semin Oncol 2:227-232, 1985 (suppl)
25. Lazarus HM, Herzig RH, Herzig GP, et al: Central nervous system toxicity of high dose cytarabine arabinoside. Cancer 48:2577-2582, 1981
26. Hwang TL, Yung WKA, Estey EH, et al: Central nervous system toxicity with high dose ara-C. Neurology 35:1475-1479, 1985
27. Winkelman MD, Hines JD: Cerebellar degeneration caused by high-dose cytosine arabinoside: A clinicophatological study. Ann Neurol 14:520-527, 1983
28. Herzig RH, Hines JD, Herzig GP, et al: Cerebellar toxicity with high-dose cytarabine arabinoside. J Clin Oncol 5:927-932, 1987
29. Sylvester RK, Fisher AJ, Lobell M: Cytarabine-induced cerebellar syndrome: Case report and literature review. Drug Intell Clin Pharm 21:177-180, 1987
30. Grossman L, Baker MA, Sutton DMC, et al: Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol 11:246-250, 1983